104.48

1.92% 1.97

Ligand Pharmaceuticals Inc (LGND)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Ligand Pharmaceuticals Inc stock is traded at $104.48, with a volume of 148.63K. It is up +1.92% in the last 24 hours and up +0.61% over the past month. Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Previous Close:

$102.51

Open:

$102.08

24h Volume:

148.63K

Relative Volume:

1.29

Market Cap:

$2.11B

Revenue:

$152.42M

Net Income/Loss:

$45.24M

P/E Ratio:

41.63

EPS:

2.51

Net Cash Flow:

$6.97M

1W Performance:

-4.49%

1M Performance:

+0.61%

6M Performance:

-13.83%

1Y Performance:

+21.32%

1-Day Range:

$102.08

$107.15

1-Week Range:

$99.24

$109.20

52-Week Range:

$77.42

$129.90

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name

Ligand Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

858-550-7500

Address

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Employee

Twitter

@Ligand_LGND

Next Earnings Date

2025-02-18

Latest SEC Filings

LGND's Discussions on Twitter

Compare LGND with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LGND Ligand Pharmaceuticals Inc	104.48	2.11B	152.42M	45.24M	6.97M	2.51
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-25	Initiated	Stifel	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-30-24	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Resumed	Stephens	Overweight
Feb-04-21	Reiterated	H.C. Wainwright	Buy
Oct-06-20	Initiated	Barclays	Overweight
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-03-19	Reiterated	H.C. Wainwright	Buy
Mar-06-19	Reiterated	H.C. Wainwright	Buy
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy
Sep-11-18	Reiterated	Argus	Buy
Aug-17-18	Initiated	Goldman	Neutral
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy
Dec-27-17	Reiterated	H.C. Wainwright	Buy
Sep-05-17	Resumed	H.C. Wainwright	Buy
Oct-05-16	Reiterated	H.C. Wainwright	Buy
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell
Mar-11-16	Initiated	Sidoti	Buy
Mar-03-16	Initiated	H.C. Wainwright	Buy

View All

Ligand Pharmaceuticals Inc Stock (LGND) Latest News

07:01 AM

Oppenheimer Maintains Rating and Raises Price Target for LGND | - GuruFocus

07:01 AM

02:04 AM

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript - Insider Monkey

02:04 AM

May 09, 2025

Oppenheimer Maintains Rating and Raises Price Target for LGND | LGND Stock News - GuruFocus

May 09, 2025

Oppenheimer Raises Price Target for Ligand (LGND) to $145 | LGND Stock News - GuruFocus

May 09, 2025

Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating - marketscreener.com

May 09, 2025